In light of the recent announcement by Vice President Joe Biden to infuse the US cancer research program with $1 billion, a so-called “Moon Shot” program, we are speaking today with Giulio Draetta, a clinician and cancer researcher at MD Anderson Cancer Center at the University of Texas in Houston, who leads that center’s Moon Shots program.
Skin Cancer / Melanoma Targets
The PD-1‒targeting drug nivolumab combined with stereotactic radiation may work synergistically and help improve overall survival while resulting in minimal neurotoxicity in brain metastatic melanoma patients.
Somatic immune system gene variants predict the survival time of patients with cutaneous melanoma, and might augment existing clinical and pathologic prognostic tools, report researchers at New York University’s Langone Medical Center and Perlmutter Cancer Center.
Dose-determining phase I clinical trials may not correctly determine the appropriate doses of small molecule oncology drugs to administer in larger, later stage trials.
Researchers at Oregon State University (OSU) are reporting that they have come up with a new nanotech drug delivery system that may combat melanoma in a whole new way.
A 32-year-old woman presents with a cutaneous nodule and a biopsy is performed. What is your diagnosis?
Gut bacteria improve antitumor immunity and the efficacy of antitumor immune checkpoint-blockade therapy, according to a pair of recently published studies..
Genetic mutation analysis confirms the malignant potential of intermediate skin lesions that are neither benign moles nor yet melanomas.
Ipilimumab (Yervoy, Bristol Myers Squibb) is now approved by the Food and Drug Administration (FDA) as an adjuvant therapy for stage III melanoma patients.
Avelumab, an investigational fully human monoclonal IgG1 antibody against programmed death-ligand 1 (anti-PD-L1), is receiving orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of Merkel cell carcinoma.